Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunocore Holdings Plc ADR (NQ: IMCR )

36.02 +1.22 (+3.51%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 283,322
Open 35.00
Bid (Size) 35.99 (1)
Ask (Size) 36.58 (10)
Prev. Close 34.80
Today's Range 34.68 - 36.31
52wk Range 33.05 - 76.98
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
From Immunocore Holdings plc
Via GlobeNewswire
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga

Performance

YTD
-49.72%
-49.72%
1 Month
-15.72%
-15.72%
3 Month
-43.26%
-43.26%
6 Month
-49.72%
-49.72%
1 Year
-38.49%
-38.49%

More News

Read More
Analyst Expectations For Immunocore Hldgs's Future
Via Benzinga
Where Immunocore Hldgs Stands With Analysts
Via Benzinga
Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Via Benzinga
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore to present at the Jefferies Global Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
From Immunocore Holdings plc
Via GlobeNewswire
Key Takeaways From Immunocore Hldgs Analyst Ratings
Via Benzinga
Immunocore Hldgs's Earnings: A Preview
Via Benzinga
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
IMCR Stock Earnings: Immunocore Hldgs Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Immunocore reports first quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore announces upcoming presentation and posters at ASCO 2024
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
Via InvestorPlace
Immunocore presented two posters at CROI 2024
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore Prices Upsized Convertible Senior Notes Offering
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore Announces Proposed Convertible Senior Notes Offering
From Immunocore Holdings Limited
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.